Akademik Veri Yönetim Sistemi
3rd International Multidisciplinary Cancer Research Congress, İstanbul, Türkiye, 7 - 10 Eylül 2023, ss.82, (Özet Bildiri)
Introduction and Aim: Breast cancer is the most frequently diagnosed cancer in women and doxorubicin is common used chemotherapy drug in the treatment of many cancer types including metastatic breast cancer. Cancer cells with a negative response to the treatment of doxorubicin trigger drug resistance. Urothelial carcinoma-associated 1 (UCA1) is long non-coding RNA (lncRNA), known to be overexpressed in breast tumorigenesis, but its role in chemotherapy resistance is largely unknown. The aim of this study was to investigate the role of UCA1 in proliferation and cell motility in doxorubicin resistance MCF-7 cell line. Materials and Methods: Previously developed doxorubicin resistant MCF-7 cells (MCF-7/Dox) up to 640 nM were used. In order to transfect small interfering RNAs (siRNAs) specifically targeting lncRNA UCA1 purchased from Ambion (USA), LipofectMax (A.B.T Biosciences, Turkey) protocol was used according to the modified manufacturer’s instructions. At 48 h after transfection, the cells were used to analyze cell viability and wound healing assay. Results: According to MTT results, the inhibition concentration (IC50) value of doxorubicin in MCF7/Dox cells was determined as 128.5 µM. UCA1 silencing was confirmed by qRT-PCR. After UCA1 silencing, it was determined that the IC50 value of doxorubicin on MCF-7/Dox cells as 88.5 µM. Finally, the cell motility decreased after silencing the UCA1 gene in MCF-7/Dox cell line.